Leflokin (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing the resealing of DNA strands, it causes lethal double‑strand breaks, leading to rapid bacterial cell death across a wide range of Gram‑negative and Gram‑positive organisms.

The specific dose and infusion rate of Leflokin are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local guidelines. Healthcare professionals should follow the product label and institutional protocols when prescribing.

Levofloxacin is classified as a pregnancy‑category drug with limited safety data. It should be used only when the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare provider, as the drug can be excreted in milk.

To order Leflokin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Leflokin (levofloxacin) offers once‑daily dosing for many infections and has a broad spectrum covering both Gram‑negative and Gram‑positive pathogens. Compared with older fluoroquinolones, it often provides higher potency against respiratory pathogens and a more favorable safety profile, though class‑related risks remain.

Leflokin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Leflokin is given by intravenous infusion. The solution is typically diluted in compatible IV fluids and infused over a period recommended by the prescriber, usually ranging from 30 minutes to 1 hour, depending on the dose and clinical situation.

Serious adverse events include tendon rupture (especially the Achilles tendon), QT‑interval prolongation that can lead to arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored for these events, particularly if risk factors are present.

Leflokin is contraindicated in patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, and used with caution in patients with significant cardiac, renal, or hepatic impairment.